Andrew T Kuykendall1, Eric Padron2. 1. H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA. Andrew.Kuykendall@moffitt.org. 2. H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA.
Abstract
PURPOSE OF REVIEW: MDS/MPNs comprise a group of rare hematologic malignancies that balance features of myeloproliferation and bone marrow failure. Given overlapping clinical features and rarity of incidence, MDS/MPNs have long posed a diagnostic and therapeutic challenge. Herein, we sought to review recent advances in diagnosis and emerging therapeutic strategies and highlight the upcoming ABNL MARRO study which aims to individualize therapy for patients with MDS/MPN. RECENT FINDINGS: Focused study of molecular mutations in MDS/MPNs has provided improved diagnostic clarity. Specific gene mutation or patterns of mutation have been increasingly described and have helped to distinguish between clinically similar diseases. While the current treatment landscape consists largely of therapies that have been co-opted from related disease, the emergence of prospective clinical trials specifically focused on MDS/MPN and the increased use of targeted agents represent progress for patients with MDS/MPN. An improved understanding of the molecular drivers of myeloid diseases has provided diagnostic clarity and renewed hope of targeted therapies for MDS/MPN patients. The upcoming ABNL MARRO study hopes to leverage this knowledge to match patients with targeted therapeutic options specific to molecular drivers of their disease.
PURPOSE OF REVIEW: MDS/MPNs comprise a group of rare hematologic malignancies that balance features of myeloproliferation and bone marrow failure. Given overlapping clinical features and rarity of incidence, MDS/MPNs have long posed a diagnostic and therapeutic challenge. Herein, we sought to review recent advances in diagnosis and emerging therapeutic strategies and highlight the upcoming ABNL MARRO study which aims to individualize therapy for patients with MDS/MPN. RECENT FINDINGS: Focused study of molecular mutations in MDS/MPNs has provided improved diagnostic clarity. Specific gene mutation or patterns of mutation have been increasingly described and have helped to distinguish between clinically similar diseases. While the current treatment landscape consists largely of therapies that have been co-opted from related disease, the emergence of prospective clinical trials specifically focused on MDS/MPN and the increased use of targeted agents represent progress for patients with MDS/MPN. An improved understanding of the molecular drivers of myeloid diseases has provided diagnostic clarity and renewed hope of targeted therapies for MDS/MPN patients. The upcoming ABNL MARRO study hopes to leverage this knowledge to match patients with targeted therapeutic options specific to molecular drivers of their disease.
Authors: E Montefusco; G Alimena; F Lo Coco; M R De Cuia; Y Z Wang; M A Aloe Spiriti; F Mancini; M Cedrone; M Mancini; F Mandelli Journal: Ann Hematol Date: 1992-07 Impact factor: 3.673
Authors: Uwe Platzbecker; Ulrich Germing; Katharina S Götze; Philipp Kiewe; Karin Mayer; Jörg Chromik; Markus Radsak; Thomas Wolff; Xiaosha Zhang; Abderrahmane Laadem; Matthew L Sherman; Kenneth M Attie; Aristoteles Giagounidis Journal: Lancet Oncol Date: 2017-09-01 Impact factor: 41.316
Authors: Ruben A Mesa; Xiaopan Yao; Larry D Cripe; Chin Yang Li; Mark Litzow; Elisabeth Paietta; Jacob M Rowe; Ayalew Tefferi; Martin S Tallman Journal: Blood Date: 2010-07-22 Impact factor: 22.113
Authors: Andrew H Wei; Stephen A Strickland; Jing-Zhou Hou; Walter Fiedler; Tara L Lin; Roland B Walter; Anoop Enjeti; Ing Soo Tiong; Michael Savona; Sangmin Lee; Brenda Chyla; Relja Popovic; Ahmed Hamed Salem; Suresh Agarwal; Tu Xu; Kaffa M Fakouhi; Rod Humerickhouse; Wan-Jen Hong; John Hayslip; Gail J Roboz Journal: J Clin Oncol Date: 2019-03-20 Impact factor: 44.544